Bristol-Myers Squibb Co. vs Eli Lilly & Co.
BMY vs LLY — side-by-side comparison from reported financials. BMY leads 4, LLY leads 7 of 11 comparable metrics.
Bristol-Myers Squibb Co.
BMY · Healthcare
$59.14-0.75%Solid
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | BMY | LLY |
|---|---|---|
| Price | $59.14 | $1 177.20 |
| Market cap | $121B | $1.05T |
| Revenue (TTM) | $49.2B | $79.7B |
| Revenue growth | +1.4% | +31.7% |
| Net margin | 18.9% | 33.5% |
| Free cash flow | $11.4B | $18.2B |
| Net cash (debt) | ($34.4B) | ($35.2B) |
| 1-year price return | +32.4% | +37.6% |
| P/E | 13.0 | 41.6 |
| P/E vs own history (cheap-side %) | 90% | 88% |
| Dividend yield | 6.28% | 0.52% |
| Return on equity | 47% | 93% |
| Altman Z-score | 2.16 | 7.10 |
| CV checks passed | 11 of 11 | 11 of 11 |
| Employees | 32,500 | 50,000 |
Full résumé-style profiles: BMY CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.